Share Analysis

The following overview contains studies carried out by banks, securities firms and independent analysts. Comments, evaluations and recommendations have been made on the IBS share. No guarantee can be made for the completeness of the list.

2009

Dr. Kalliwoda Research - Company growth without any set-backs so far - target price 5,20 € - 19.05.2009

2008

Dr. Kalliwoda Research: "outlook confirmed" - target price 5,49 € - 10.11.2008

Please note that the reports and valuations, to which the afore-mentioned links provide access, are solely those of the respective analyst institutes. IBS accepts no liability for, nor can it vouch for any third party content in terms of § 5 TDG (German Remote Services Statute).

IBS:infopool

Füllen Sie die Daten aus und wählen Sie aus den angebotenen Dokumenten, diese werden Ihnen mit dem absenden des Formulars an Ihre angegebene eMail gesendet.

Ihre Daten